Alzheimer

Antipsychotic Drugs Shorten Lifespan of Alzheimer's Patients

Wednesday, January 21, 2009 by: Kathlyn Stone
Tags: antipsychotic drugs, health news, Natural News

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
Biologist explains how marijuana causes tumor cells to commit suicide
Depopulation test run? 75% of children who received vaccines in Mexican town now dead or hospitalized
BAM! Chipotle goes 100% non-GMO; flatly rejecting the biotech industry and its toxic food ingredients
Companies begin planting microchips under employees' skin
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
NJ cops bust teenagers shoveling snow without a permit
Russia throws down the gauntlet: energy supply to Europe cut off; petrodollar abandoned as currency war escalates
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
Chemotherapy kills cancer patients faster than no treatment at all
Why flu shots are the greatest medical fraud in history
600 strains of an aerosolized thought control vaccine already tested on humans; deployed via air, food and water
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
Flu vaccine kills 13 in Italy; death toll rises
The 21 curious questions we're never allowed to ask about vaccines
Vicious attack on Dr. Oz actually waged by biotech mafia; plot to destroy Oz launched after episode on glyphosate toxicity went viral
Orthorexia Nervosa - New mental disorder aimed at people who insist on eating a clean diet
Whooping cough outbreak at Massachusetts high school affected only vaccinated students

Delicious
(NaturalNews) A UK research study finds that prescribing antipsychotic drugs "off-label" to calm Alzheimer's patients nearly doubles the risk of patient death over three years. New antipsychotic drugs such as Risperdal, Seroquel and Zyprexa are routinely prescribed to manage aggressiveness and agitation in Alzheimer's patients. A new study finds that these antipsychotics nearly double elderly patients' risk of death over three years, according to a new study published in the January 9 issue of Lancet Neurology.

In a study of 165 Alzheimer's patients in the UK who were prescribed either antipsychotics or placebos, researchers found a significant increase in the risk of death for patients who continued taking the antipsychotic medication. The difference between the two groups became more pronounced over time, with 24-month survival rates for antipsychotic-treated patients falling to 46% versus 71% on the placebo and at 36 months it was 30% versus 59%. After three years, less than a third of people on antipsychotics were alive compared to nearly two-thirds that were given the placebo. The illnesses associated with over-medication for long periods include stroke, loss of brain function, Parkinsonianism and chest infections.

The study was led by Dr. Clive Ballard of King's College in London and funded by the Alzheimer's Research Trust, a UK charity.

"The results further highlight the need to seek less harmful alternatives for the long-term treatment of behavioral symptoms in Alzheimer's patients," said Ballard in a written statement. "At the moment, there is still a limited place for antipsychotics in the treatment of Alzheimer's, particularly severe aggression, but the serious concerns of the drugs shown by our research emphasize the urgent need to put an end to unnecessary and prolonged prescribing."

As any caregiver of an Alzheimer's disease patient knows, the disease can bring some difficult symptoms: irritability, anxiety, aggressiveness, confusion and agitation. With shortages in trained staff adept at caring for Alzheimer's patients, physicians have turned increasingly to the use of antipsychotic drugs in an effort to manage these symptoms, despite Food and Drug Administration warnings.

The FDA has not approved these drugs for Alzheimer's patients but physicians have the discretion to prescribe them to elderly people with dementia as "off label."

Up to 100,000 people with dementia are prescribed antipsychotics in UK nursing homes. In the United States, between 30 and 60 percent of the 1.8 Americans living in nursing homes have been prescribed antipsychotic drugs to control their behavior, according to the Alzheimer's Association.

If antipsychotics are used, it should only be as a last resort and for a short period of time (6-12 weeks), according to the experts.

About the author

Kathlyn Stone is an independent journalist in St. Paul, MN covering health care news and policies for public and professional audiences. She is the publisher of FleshandStone.net.

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.